Friday, January 22, 2016 9:18:16 AM
CASI Pharmaceuticals Inc (NASDAQ:CASI) COO Cynthia W. Hu purchased 16,800 shares of CASI Pharmaceuticals stock in a transaction dated Tuesday, January 19th. The stock was acquired at an average price of $0.72 per share, with a total value of $12,096.00. Following the acquisition, the chief operating officer now owns 17,785 shares in the company, valued at approximately $12,805.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
CASI Pharmaceuticals Inc (NASDAQ:CASI) traded down 4.05% during midday trading on Thursday, hitting $0.71. 8,056 shares of the stock traded hands. The company’s 50-day moving average is $0.93 and its 200 day moving average is $1.24. CASI Pharmaceuticals Inc has a 12-month low of $0.58 and a 12-month high of $2.13. The firm’s market cap is $23.04 million.
CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Friday, November 13th. The company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.02. On average, analysts anticipate that CASI Pharmaceuticals Inc will post ($0.19) EPS for the current fiscal year.
Separately, HC Wainwright assumed coverage on shares of CASI Pharmaceuticals in a report on Thursday, October 29th. They issued a “buy” rating and a $3.00 price target for the company
Recent CASI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/12/2024 11:30:34 AM
- CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE • PR Newswire (US) • 09/04/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/04/2024 04:15:05 AM
- Form F-3/A - Registration statement by foreign private issuers: [Amend] • Edgar (US Regulatory) • 08/29/2024 12:00:51 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/16/2024 09:01:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 12:30:21 PM
- CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 08/16/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 10:18:15 AM
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 07/19/2024 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/19/2024 10:07:25 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/08/2024 11:48:21 AM
- CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP • PR Newswire (US) • 07/08/2024 11:30:00 AM
- CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company • PR Newswire (US) • 06/26/2024 08:15:00 PM
- CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He • PR Newswire (US) • 06/26/2024 08:10:00 PM
- CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) • PR Newswire (US) • 05/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 10:50:28 AM
- CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 05/14/2024 12:00:00 PM
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 04/08/2024 09:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 03/28/2024 11:00:00 AM
- CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China • PR Newswire (US) • 03/05/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA • PR Newswire (US) • 02/16/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 11/14/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA • PR Newswire (US) • 11/08/2023 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM